Detalhe da pesquisa
1.
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
J Cell Mol Med
; 28(9): e18342, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38693852
2.
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.
Future Oncol
; 2024 Apr 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38647011
3.
Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
Int J Mol Sci
; 25(9)2024 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38732087
4.
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 24(4): 347-359, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36868252
5.
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
N Engl J Med
; 390(10): 944-946, 2024 Mar 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38446680
6.
Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset.
BJU Int
; 130(6): 754-763, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34928524
7.
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.
Molecules
; 26(5)2021 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33673611
8.
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
Br J Cancer
; 122(4): 453-454, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31857721
9.
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
BMC Cancer
; 20(1): 230, 2020 Mar 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32188412
10.
Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.
World J Urol
; 38(8): 1959-1968, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31691084
11.
Many Different LINE-1 Retroelements Are Activated in Bladder Cancer.
Int J Mol Sci
; 21(24)2020 Dec 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33322422
12.
Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.
World J Urol
; 37(10): 2081-2090, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-30643974
13.
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
Int J Mol Sci
; 20(9)2019 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31052182
14.
Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
Urol Int
; 101(2): 224-231, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30045033
15.
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
Int J Mol Sci
; 19(2)2018 Feb 16.
Artigo
Inglês
| MEDLINE | ID: mdl-29462944
16.
Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.
Int J Mol Sci
; 18(8)2017 Aug 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28767070
17.
The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.
Mol Cancer
; 14: 108, 2015 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25994132
18.
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
Oncology
; 89(2): 70-8, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25765871
19.
Canonical Notch signalling is inactive in urothelial carcinoma.
BMC Cancer
; 14: 628, 2014 Aug 29.
Artigo
Inglês
| MEDLINE | ID: mdl-25167871
20.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
BJU Int
; 113(5b): E137-43, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24219029